Billionaire John Paulson’s Latest Portfolio: Top 5 Stock Picks

2. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Paulson & Co’s Stake Value: $646,560,000

Percentage of Paulson & Co’s 13F Portfolio: 19.93%

Number of Hedge Fund Holders: 58

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a biotech company that develops medication for rare, autoimmune, and inflammatory diseases. John Paulson owns 6 million shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) as of Q4 2021, worth $646.5 million, representing 19.93% of the billionaire’s total holdings. 

On March 1, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) reported its Q4 financial results, posting earnings per share of $1.41, beating estimates by $0.06. Revenue for the quarter increased 36.11% year-over-year to $1.01 billion, surpassing market consensus by $18.57 million. 

Oppenheimer analyst Leland Gershell initiated coverage of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) on March 14 with an Outperform rating and a $140 price target. The analyst contended that the company’s core products, Tepezza and Krystexxa, have “significant sales growth potential” for thyroid eye disease and chronic refractory gout. He also sees potential for Uplizna as the “preferred therapy” for neuromyelitis optica spectrum disorders.

Among the hedge funds tracked by Insider Monkey, 58 funds were long Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in the December quarter, with collective stakes amounting to $4.46 billion. Kurt Von Emster’s VenBio Select Advisor is the leading shareholder of the company, with 9.2 million shares worth more than $1 billion. 

Here is what Carillon Tower Advisers has to say about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in their Q1 2021 investor letter:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”